StockTipsArenaBeta

BUY Narayana Hrudayalaya Ltd. — Dharmesh Kant, Cholamandalam Securities

BUYNarayana Hrudayalaya Ltd.
Narayana Hrudayalaya share price target & all analyst calls

byDharmesh Kant, Cholamandalam SecuritiesHorizon: NA (inferred 1–3 months)6 Nov 2026via CNBC Awaaz.

Entry₹1,898.4Inferred
Target₹2,100
Total upside +10.62%
Stop lossNot given
CMP₹1,9031d ago
Active+0.24%+10.35%upside left 3 mo left
Follow Dharmesh Kant for new callsGet alertsWatch NH for new buy/sell callsGet alertsSee 1 other Short-term call on NHSee 73 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:28 pm IST
6 supporting2 neutral1 opposing
Supports the BUY call (6)

MACD above its signal line — bullish momentum

Technicals · macd·7 Nov · today

5 advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · adjacent horizon·3 Nov · 4d ago

Narayana Hrudayalaya Q2 Results: Net profit surges on higher patient volumes, complex procedures

NewsCnbc-Tv18·30 Oct · 1w ago

(opens in new tab)

Narayana Hrudayalaya reported Q2 FY27 consolidated revenue of 28,440 Mn (up 73% YoY) and EBITDA of 6,054 Mn (up 42% YoY), driven by strong performance in India and Cayman operations.

NSE · Press Release·30 Oct · 1w ago

(opens in new tab)

Narayana Hrudayalaya reported Q2 FY27 consolidated revenue of ₹28,440 Mn (up 73% YoY) and EBITDA of ₹6,054 Mn (up 42% YoY), driven by strong performance in India and Cayman operations.

BSE · Company Update·30 Oct · 1w ago

(opens in new tab)
Neutral / worth noting (2)

The NCLT Bengaluru Bench sanctioned the scheme of arrangement between NH Integrated Care Private Limited and Narayana Hrudayalaya Limited.

BSE · Company Update·4 Nov · 2d ago

(opens in new tab)

Outcome of the Board meeting for unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026.

BSE · Board Meeting·30 Oct · 1w ago

(opens in new tab)
Weighs against the BUY call (1)

RSI at 71 — overbought territory

Technicals · rsi·7 Nov · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Narayana Hrudayalaya

All analyst calls on Narayana Hrudayalaya

More from Dharmesh Kant, Cholamandalam Securities

Every call and its outcome